Circulating and Disseminated Tumour Cells in Breast Carcinoma

Abstract

Haematogenic dissemination of tumour cells in breast carcinoma is among the most intensively researched areas in translational oncology. Large meta-analyses have shown the prognostic relevance of the disseminated tumour cells in the bone marrow and circulating tumour cells in the peripheral blood in the adjuvant as well as metastatic setting. The current status of the research was discussed in detail during the annual meeting of the German Society of Senology in Berlin. The following conference report gives an overview of the clinical study landscape and the new methodological developments for improving the detection and phenotyping of the circulating and disseminated tumour cells.

Key words

tumour cell dissemination - circulating tumour cells - disseminated tumour cells - breast carcinoma

• References/Literatur

• 1 Braun S, Vogl FD, Naume B. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802
• 2 Bidard FC, Peeters DJ, Fehm T. et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014; 15: 406-414
• 3 Janni WJ, Rack B, Terstappen LW. et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clin Cancer Res 2016; 22: 2583-2593
• 4 Bidard FC, Michiels S, Riethdorf S. et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst 2018; 110: 560-567
• 5 Park Y, Kitahara T, Urita T. et al. Expected clinical applications of circulating tumor cells in breast cancer. World J Clin Oncol 2011; 2: 303-310
• 6 Harb W, Fan A, Tran T. et al. Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay. Transl Oncol 2013; 6: 528-538
• 7 Saucedo-Zeni N, Mewes S, Niestroj R. et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol 2012; 41: 1241-1250
• 8 Gorges TM, Penkalla N, Schalk T. et al. Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells. Clin Cancer Res 2016; 22: 2197-2206
• 9 Hvichia GE, Parveen Z, Wagner C. et al. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer 2016; 138: 2894-2904
• 10 Fischer JC, Niederacher D, Topp SA. et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A 2013; 110: 16580-16585
• 11 Rack B, Schindlbeck C, Jückstock J. et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014;
• 12 Janni W, Vogl FD, Wiedswang G. et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse–a European pooled analysis. Clin Cancer Res 2011; 17: 2967-2976
• 13 Sparano JA, OʼNeill A, Alpaugh K. et al. Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II – III breast cancer. SABCS 2017; Abstr. GS6-03.
• 14 Sparano J, OʼNeill A, Alpaugh K. et al. Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2018;
• 15 Janni W, Rack B, Fasching P. et al. Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial. J Clin Oncol 2018;
• 16 Aktas B, Weydandt L, Westerwick D. et al. Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients. Cancer Res 2018; 78 (4 Suppl.): PD3-02 doi:10.1158/1538-7445.SABCS17-PD3-02
• 17 Ignatiadis M, Litiere S, Rothe F. et al. Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial. Ann Oncol 2018;
• 18 Hosseini H, Obradovic MM, Hoffmann M. et al. Early dissemination seeds metastasis in breast cancer. Nature 2016;
• 19 Narod SA, Iqbal J, Giannakeas V. et al. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol 2015; 1: 888-896
• 20 Walter VP, Taran FA, Wallwiener M. et al. Detection of disseminated tumor cells in DCIS patients impacts local recurrence. SABCS 2017; Abstr. P1-01 – 16.
• 21 Banys M, Solomayer EF, Gebauer G. et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 2013; 13: 480
• 22 Smerage JB, Barlow WE, Hortobagyi GN. et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014; 32: 3483-3489
• 23 Banys-Paluchowski M, Krawczyk N, Meier-Stiegen F. et al. Circulating tumor cells in breast cancer–current status and perspectives. Crit Rev Oncol Hematol 2016; 97: 22-29
• 24 Bidard F-C, Cottu P, Dubot C. et al. Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial (117P). Ann Oncol 2017; 28: v22-v42
• 25 Schramm A, Friedl TW, Schochter F. et al. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet 2016; 293: 271-281